Novavax, Inc. revenue for the last year amounted to 682.16 M USD, the most of which — 190.21 M USD — came from its highest performing source at the moment, Innovative Vaccines, the year earlier bringing 531.39 M USD. The greatest contribution to the revenue figure was made by Europe — last year it brought Novavax, Inc. 93.27 M USD, and the year before that — 268.36 M USD.